Medical Expert Psychiatry (m/f/d)

HMNC Brain Health (HMNC) is a clinical-stage neuroscience company developing new therapies for mental health disorders. With an initial focus on difficult-to-treat depression, including treatment-resistant depression (TRD) and adjunctive therapies for major depressive disorder (MDD), HMNC's pipeline includes two late-stage programs. Lead asset Ketabon (KET01), partnered with MEDICE for European commercialization, is an oral prolonged-release ketamine formulation for TRD, designed for at-home use. Nelivabon (BH-200) is a first-in-class oral vasopressin receptor antagonist targeting the stress axis, with potential in adjunctive MDD/ TRD. By advancing targeted and accessible treatment options, HMNC aims to address significant unmet needs of millions of patients who are not helped sufficiently by existing mental health therapies. The Company is headquartered in Munich, Germany. Find out more at and connect with us on LinkedIn .

CLTRD1_DE